Efficacy and safety of different doses of subcutaneous galcanezumab in chronic and episodic migraine: A pooled analysis of 3651 patients

Authors
Category Systematic review
JournalNeurology
Year 2023
This article has no abstract
Epistemonikos ID: a6f494da8ea6161bb2522cc70701a89dbba1cc82
First added on: Feb 16, 2025